99mTc-Hydrazinonicotinic acid-Glu-[cyclo(Arg-Gly-Asp-D-Phe-Lys)]2

99mTc-HYNIC-E-[c(RGDfK)]2

Leung K.

Publication Details

Image

Table

In vitro Rodents

Background

[PubMed]

Integrins are a family of heterodimeric glycoproteins on cell surfaces that mediate diverse biological events involving cell–cell and cell–matrix interactions (1). Integrins consist of an α and a β subunit and are important for cell adhesion and signal transduction. The αvβ3 integrin is the most prominent receptor affecting tumor growth, tumor invasiveness, metastasis, tumor-induced angiogenesis, inflammation, osteoporosis, and rheumatoid arthritis (2-7). Expression of the αvβ3 integrin is strong on tumor cells and activated endothelial cells, whereas expression is weak on resting endothelial cells and most normal tissues. Antagonists of αvβ3 are being studied as antitumor and antiangiogenic agents, and the agonists of αvβ3 are being studied as angiogenic agents for coronary angiogenesis (6, 8, 9). A tripeptide sequence consisting of Arg-Gly-Asp (RGD) has been identified as a recognition motif used by extracellular matrix proteins (vitronectin, fibrinogen, laminin, and collagen) to bind to a variety of integrins, including αvβ3. Various radiolabeled antagonists have been introduced for imaging of tumors and tumor angiogenesis (10).

Most cyclic RGD peptides are composed of five amino acids. Haubner et al. (11) reported that various cyclic RGD peptides exhibit selective inhibition of binding to αvβ3 (inhibition concentration (IC50), 7–40 nM) but not to integrins αvβ5 (IC50, 600–4,000 nM) or αIIbβ3 (IC50, 700–5,000 nM). Various radiolabeled cyclic RGD peptides have been found to have high accumulation in tumors in nude mice (12). Hydrazinonicotinic acid (HYNIC) is a coupling agent for 99mTc labeling of peptides that can achieve high specific activities without affecting the receptor-binding ability of the amino acid sequence. 99mTc is bound to the hydrazine group, and other coordination sites can be occupied by one or more coligands. Liu et al. (13) reported the success of radiolabeling the cyclo(Arg-Gly-Asp-D-Phe-Lys) (c(RGDfK)) dimer linked by glutamic acid that was conjugated with HYNIC. Trisodium triphenylphosphine-3,3’,3’’-trisulfonate (TPPTS) and tris(hydroxymethyl)-methylglycine (tricine) as coligands. 99mTc-HYNIC-E-[c(RGDfK)]2(tricine)(TPPTS) showed high tumor accumulation in nude mice bearing human tumor xenografts.

Synthesis

[PubMed]

Liu et al. (13) reported the synthesis of 99mTc-HYNIC-E-[c(RGDfK)]2(tricine)(TPPTS) by incubation of 20 μg HYNIC-E-[c(RGDyK)]2, 6.5 mg tricine, 5 mg TPPTS, and 1.85 GBq (50 mCi ) Na[99mTcO4] for 10 min at 100ºC. Radiochemical purity was >90% with a specific activity of ~370 GBq/μmol (10 Ci/μmol).

In Vitro Studies: Testing in Cells and Tissues

[PubMed]

Liu et al. (14) performed in vitro competition of 99Tc-HYNIC-E-[c(RGDfK)]2(tricine)(TPPTS) with biotinylated vitronectin. 99Tc-HYNIC-E-[c(RGDfK)]2(tricine)(TPPTS) had an IC50 value of 1.7 ± 0.5 nM. E-[c(RGDfK)]2 had an IC50 value of 0.6 ± 0.4 nM. The in vitro solution stability of 99Tc-HYNIC-E-[c(RGDfK)]2(tricine)(TPPTS) was tested by incubating the radiolabeled peptide in phosphate-buffered solution that contained 1.0 mg/ml cysteine at 37ºC for up to 6 h. No significant degradation of 99Tc-HYNIC-E-[c(RGDfK)]2(tricine)(TPPTS) was observed under these conditions. Janssen et al. (15) reported that the receptor-binding fraction of 99mTc-HYNIC-E-[c(RGDfK)]2(tricine)(TPPTS) for conditions representing infinite receptor concentration was >70% using cultured human ovarian carcinoma IGROV-1 cells.

Animal Studies

Rodents

[PubMed]

Janssen et al. (15) performed biodistribution studies of 99mTc-HYNIC-E-c(RGDfK) and 99mTc-HYNIC-E-[c(RGDfK)]2 in nude mice bearing human OVCAR-3 ovary carcinoma tumors. Tumor uptake peaked at 5.8 ± 0.7% injected dose (ID)/g (1 h) and 5.2 ± 0.6% ID/g (30 min) for the dimer and the monomer, respectively. At 1, 2, and 4 h after injection, uptake of the dimer in the tumors was significantly higher than that of the monomer. Tumor/blood ratios were similar at all time points, the highest at 24 h with a value of 63 for both compounds. At all time points, kidney accumulation of the dimer was significantly higher than kidney accumulation of the monomer. Both peptides exhibited similar accumulation in the spleen, liver, and lung.

Liu et al. (16) performed biodistribution studies of 99mTc-HYNIC-E-[c(RGDfK)]2 in nude mice bearing human MDA-MB-435 breast carcinoma tumors. Tumor uptake values were 3.50% ID/g at 5 min, 3.59% ID/g at 30 min, 3.38% ID/g at 60 min, and 3.82% ID/g at 120 min. The organ with the highest uptake was the kidney (14.33% ID/g at 120 min), followed by the intestine (4.95% ID/g at 120 min), lung (2.83% ID/g at 120 min), and liver (3.11% ID/g at 120 min). Blood levels (% ID/g) were 2.70 at 5 min, 1.66 at 30 min, 1.60 at 60 min, and 0.52 at 120 min. Co-injection of E-[c(RGDfK)]2 (30 mg/kg) resulted in a significant reduction of radioactivity in the tumor, lung, liver, spleen, and intestine. The radioactivity in the kidney and muscle was also slightly reduced. Jia et al. (17) performed single-photon emission computed tomography imaging in nude mice bearing U87MG human glioma tumors with 14.8 MBq (0.4 mCi) of 99mTc-HYNIC-E-[c(RGDfK)]2. The tumors were clearly visualized at 4 h after injection because of fast clearance of the tracer from the liver and lungs.

Other Non-Primate Mammals

[PubMed]

No publication is currently available.

Non-Human Primates

[PubMed]

No publication is currently available.

Human Studies

[PubMed]

No publication is currently available.

NIH Support

R01 CA115883-01A2

References

1.
Hynes R.O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992;69(1):11–25. [PubMed: 1555235]
2.
Jin H., Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer. 2004;90(3):561–5. [PMC free article: PMC2410157] [PubMed: 14760364]
3.
Varner J.A., Cheresh D.A. Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. Important Adv Oncol. 1996:69–87. [PubMed: 8791129]
4.
Wilder R.L. Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases Ann Rheum Dis 200261Suppl 2ii96–9. [PMC free article: PMC1766704] [PubMed: 12379637]
5.
Grzesik W.J. Integrins and bone--cell adhesion and beyond. Arch Immunol Ther Exp (Warsz) 1997;45(4):271–5. [PubMed: 9523000]
6.
Kumar C.C. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets. 2003;4(2):123–31. [PubMed: 12558065]
7.
Ruegg C., Dormond O., Foletti A. Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target? Endothelium. 2002;9(3):151–60. [PubMed: 12380640]
8.
Kerr J.S., Mousa S.A., Slee A.M. Alpha(v)beta(3) integrin in angiogenesis and restenosis. Drug News Perspect. 2001;14(3):143–50. [PubMed: 12819820]
9.
Mousa S.A. alphav Vitronectin receptors in vascular-mediated disorders. Med Res Rev. 2003;23(2):190–9. [PubMed: 12500288]
10.
Haubner R., Wester H.J. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des. 2004;10(13):1439–55. [PubMed: 15134568]
11.
Haubner R., Wester H.J., Burkhart F., Senekowitsch-Schmidtke R., Weber W., Goodman S.L., Kessler H., Schwaiger M. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 2001;42(2):326–36. [PubMed: 11216533]
12.
Chen X., Park R., Shahinian A.H., Tohme M., Khankaldyyan V., Bozorgzadeh M.H., Bading J.R., Moats R., Laug W.E., Conti P.S. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol. 2004;31(2):179–89. [PubMed: 15013483]
13.
Liu S., Edwards D.S., Ziegler M.C., Harris A.R., Hemingway S.J., Barrett J.A. 99mTc-labeling of a hydrazinonicotinamide-conjugated vitronectin receptor antagonist useful for imaging tumors. Bioconjug Chem. 2001;12(4):624–9. [PubMed: 11459468]
14.
Liu S., Hsieh W.Y., Jiang Y., Kim Y.S., Sreerama S.G., Chen X., Jia B., Wang F. Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer. Bioconjug Chem. 2007;18(2):438–46. [PubMed: 17341108]
15.
Janssen M.L., Oyen W.J., Dijkgraaf I., Massuger L.F., Frielink C., Edwards D.S., Rajopadhye M., Boonstra H., Corstens F.H., Boerman O.C. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res. 2002;62(21):6146–51. [PubMed: 12414640]
16.
Liu S., Hsieh W.Y., Kim Y.S., Mohammed S.I. Effect of coligands on biodistribution characteristics of ternary ligand 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer. Bioconjug Chem. 2005;16(6):1580–8. [PubMed: 16287258]
17.
Jia B., Shi J., Yang Z., Xu B., Liu Z., Zhao H., Liu S., Wang F. 99mTc-labeled cyclic RGDfK dimer: initial evaluation for SPECT imaging of glioma integrin alphavbeta3 expression. Bioconjug Chem. 2006;17(4):1069–76. [PubMed: 16848417]